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Prostate cancer growth is regulated in part by androgens and
hormonal ablation in the form of surgical or chemical castration is
the mainstay of treatment for men with advanced disease.
However, such treatment is palliative and eventually most tumours
become androgen-independent. New treatments are required to
treat androgen-independent disease. One method to identify new
therapeutic targets is to study molecular pathways involved in
androgen receptor (AR)-mediated signalling. 
Targeting and subsequent recruitment to the basal transcription
machinery by steroid hormone receptors (SHR) is facilitated by
sets of co-regulating proteins. Since the identification of the
homologous SW1/SNF family of proteins in yeast, co-factors of
SHRs have increased in number and complexity (Horwitz et al,
1996). These co-regulators; either co-activators or co-repressors,
appear to be crucial for the assembly of the pre-initiation complex
and recruitment of RNA polymerase II to the translation start site.
The ‘squelching’ or competitive effect that different SHR families
are able to exert on each other is thought to be due in part to
competition for these factors (Meyer et al, 1989, 1992). Promiscu-
ity of co-activators between different SHR systems mean that no
co-activator has been specifically associated with a particular
SHR. In vitro work has shown that certain co-activators can
enhance AR activity 10–30 fold (Yeh and Chang 1996; Aarnisalo
et al, 1998; Kang et al, 1999). 
RAC 3, encoded on chromosome 20q12, is a 155 kDa protein
that is a member of the p160 family of steroid receptor co-activa-
tors which include TIF 2 and SRC 1 (Li et al, 1997). It has also
been designated as AIB 1 (amplified in breast 1), ACTR, TRAM
1, p/CIP, SRC 3 and in the Human Gene Nomenclature database as
NCOA 3. For this manuscript we will hereafter refer to the gene as
RAC 3. It was first identified in a yeast 2 hybrid system using the
retinoic acid receptor as bait screening a brain cDNA library (Li
et al, 1997). In this study, RAC 3 was found to be a co-activator of
the retinoic acid receptor and enhanced its transcriptional activity.
In the same year, Anzick et al (1997) identified RAC 3 (designated
as AIB 1) as an amplified gene in breast cancer. They found that in
oestrogen receptor (ER)-positive breast cancer cell lines, RAC 3
was amplified by greater than 20 fold. Furthermore, 10/105
primary breast tumour biopsies also demonstrated similar gene
amplification. Subsequent tissue in situ hybridisation showed that
RAC 3 expression at the transcript level was increased in tumour
as compared to normal mammary epithelium in 58% of cases
studied. In in vitro studies, RAC 3 was shown to enhance ER-
dependent transcription by up to 3-fold. Bautista et al (1998) also
demonstrated that RAC 3 amplification correlated with both
tumour size and ER and progesterone receptor (PR) positivity in
primary breast cancers. It has further been shown that endogenous
RAC 3 interacts with the human ER in a ligand-dependent manner
in MCF-7 breast cancer cells (Tikkanen et al, 2000). Interestingly
the RAC 3 gene has also been found to be amplified in pancreatic
cancers and primary gastric cancers suggesting that RAC 3 is
functional in non-primarily steroid-dependent organs (Ghadimi et
al, 1999; Sakakura et al, 2000). 
RAC 3 over-expression in breast cancer and its ability to
increase ER-dependent transcription suggests a role in tumour
progression that involves interaction with the ER. In the light of
similarities between prostate and breast cancer biology, and the
fact that RAC 3 has been recently identified as an AR interacting
protein (Tan et al, 2000), we proposed to examined the role of RAC
3 in the prostate. Our goal was to determine if RAC 3 interacted
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functionally with the human AR and if RAC 3 was expressed in
prostate cancer cell lines. We then investigated expression in clin-
ical prostate material and the possible relationship between
expression levels and disease progression. 
MATERIALS AND METHODS 
Antibodies 
Goat polyclonal anti-RAC 3 (Santa Cruz, Biotech, USA) was
selected because of specific binding to the amino terminus of
the co-activator and was used in Western blots and immuno-
precipitation (IP). Also for IP and for immuno-staining, a mouse
monoclonal antibody (Affinity Bioreagents, Cambridge, UK) was
selected. This antibody was constructed from the fusion of a
myeloma cell line to splenocytes from mice immunised with a
GST fusion protein encoding residues 605–1294 of human RAC 3
(mapping to the C terminus of the protein). Mouse anti-human AR
antibody was obtained from Pharmingen (USA). 
Western analysis 
The prostate cancer cell lines: LNCaP, DU 145 and PC 3, the
breast cancer cell line MCF-7 and the monkey kidney cell line Cos
7, were cultured in RPMI 1640 media (Life Technologies, USA)
supplemented with 10% fetal calf serum (FCS) in 90-mm Petri
dishes (Corning, USA) to near confluence. Cells were washed
with phosphate-buffered saline (PBS) and harvested with SDS-
loading buffer (0.125M Tris pH 6.8, 2% sodium dodecylsulfate,
10% glycerol, 10% β mercaptoethanol and 0.01% bromophenol
blue). Cell lysates were stored at minus 70˚C. Normal human
kidney lysate was obtained by suspension of crushed whole kidney
sample in SDS buffer. 30 µ l aliquots (approximately 100 µ g) were
subjected to 10% SDS-PAGE before protein transfer to nitrocellu-
lose membranes (Hybond C, Amersham, UK). Filters were
blocked with 5% dried milk at room temperature for 1 hour. Goat
polyclonal RAC 3 antibody (1 µ gm l –1) was incubated with filters
in sealed bags at room temperature for 1 hour. Filters were then
incubated with the appropriate secondary antibody (horseradish
peroxidase conjugated) before visualisation with ECL reagents
(Amersham, UK) and exposed to autoradiographic film. Filters
were stripped with 2% SDS buffer (100 mM β mercaptoethanol,
62.5 mM Tris HCl pH 6.7) incubated at 50˚C for 30 minutes and
then re-probed with 0.5 µ gm l –1 of mouse monoclonal AR anti-
body. Loading was checked by re-stripping the filter and probing
for α tubulin (Sigma, USA). 
Immuno-precipitation 
LNCaP cells cultured in media with 10% dextran-coated charcoal
steroid-depleted serum (DCC-FCS), DCC-FCS supplemented
with 10 nM mibolerone (a synthetic androgen) or in full media as
described above were harvested with PBS containing 0.02%
EDTA solution, spun at 400 g for 5 minutes and the supernatant
discarded. Cell pellets were re-suspended twice in 1 ml of lysis
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.2 mM Na3VO4,
1 mM DTT and 25 µ gm l –1 each of Aprotinin, Leupeptin, Pepstatin
and PMSF). 20 µ l of pre-prepared protein G sepharose (PGS) was
added and the mix incubated at 4˚C for 2–4 hours. Mouse mono-
clonal AR antibody (0.5 µ gm l –1) or goat polyclonal RAC 3 anti-
body (0.2 µ gm l –1) was added and samples incubated overnight at
4˚C. Following this, a further 20 µ 1 of PGS was added to each
sample and incubated for 1 hour at room temperature. The samples
were spun down and the supernatant discarded. The resultant
pellet was washed in PBS-Triton with increasing stringency of
1× Wash 1 (PBS, 0.2% Triton–100, 350 mM NaCl) and 2 × Wash
2 (PBS, 0.2% Triton–100). Pellets were re-suspended in 40 µ l of
SDS sample buffer and resolved by SDS-PAGE. Western analysis
was then performed using the appropriate antibody. Controls of
cell extract only and antibody only were taken through the
immuno-precipitation steps and probed simultaneously. 
Cell culture and transfection assays 
The following mammalian expression plasmids were kindly
received; pCMX.RAC 3 full length incorporating a FLAG tag
(Dr Don Chen, Massachusetts University, USA) and pSG5.ELE
1α (Dr B Peeters, University of Leuven, Belgium). pPSA.1uc, a
reporter construct containing 2 androgen response elements and
human AR cloned into the pCDNA3 vector have been previously
described (Brady et al, 1999). Empty pSG5 vector was used to
normalise the amount of DNA transfected in each experiment. DU
145 cells were seeded at 25 000 cells well–1 in a 24-well plate
(Corning). These were then transfected using Superfect (Qiagen)
for a period of 2 hours (50 ng pCDNA3.AR, 125 ng pPSA.1uc,
200 ng pCMV.β gal and 200 ng pCMX.RAC 3, pSG5.Ele1α (a
known AR co-activator) or empty pSG5) and then washed with
PBS. Cos 7 cells were seeded at 20 000 cells well–1 in a 24-well
plate. These were transfected using Superfect for a period of 2
hours (50 ng pCDNA3.AR, 125 ng pPSA.1uc, 200 ng pCMV.β gal
and 200 ng pCMX.RAC 3 or empty pSG5) and then washed with
PBS. DCC FCS media only or supplemented with 10 nM
mibolerone was then added and the cells incubated for 36–40
hours. Cells were harvested and assayed for luciferase activity
according to manufacturers recommendations (Promega, UK)
for 15–60 minutes. Luciferase activity was corrected for trans-
fection efficiency by the corresponding β -galactosidase activity.
β -galactosidase assays were typically performed in a 96-well
plate (Corning, USA) as follows: sample extracts were incubated
with an equal volume of β -galactosidase 2 × assay buffer
(Promega, UK) and the reaction terminated with the addition of
1.5 volumes of 1 M sodium carbonate. A420 values were then
obtained using an MR5000 plate reader (Dynatech, UK) and
activity calculated. 
In situ hybridization 
Plasmid pT7T3D containing cDNA encoding 957 bp of RAC 3
was obtained from the I.M.A.G.E consortium (Clone ID 1256276,
Acc No AA738120). The plasmid was purified and sequenced
prior to use and verified against the published sequence of RAC 3
(Acc No AF012108). This clone mapped to the 3′ end of the gene
and showed 99% homology using the NCBI BLAST program.
Plasmid DNA was linearised with the restriction enzymes Not I or
Eco RI. In vitro transcription was carried out to generate the anti-
sense and sense probes using RNA polymerase. Digoxigenin–11-
2′ deoxyuridine 5′ -triphosphate was incorporated into the
riboprobes (Boehringer, UK). RNA dot blot was used to quantify
the amount of probe obtained. 50 µ l of hybridisation mix (50%
formamide, 4 × SSC, 1 × Denharts, 125 µ gm l –1 of tRNA) at a
concentration of 0.5 ng riboprobe µ l–1 was added to each section
and a coverslip applied. Hybridisation was carried out in a sealed1930 VJ Gnanapragasam et al
British Journal of Cancer (2001) 85(12), 1928–1936 © 2001 Cancer Research Campaign
humidification chamber at 52˚C overnight. A 1 in 500 dilution of
alkaline  phosphatase conjugated sheep anti-digoxigenin serum
(Boehringer, UK) was incubated with the sections for 2 hours to
detect bound digoxigenin-labelled probe. Signals were visualised
by incubation with 5 bromo-4 chloro-3 indolyl phosphate and
nitroblue tetrazolium for 18 hours in darkness. Signals were
described as present or absent. All section were counter-stained
with haematoxylin which identified the cellular architecture. 
Immuno-histochemistry 
Immuno-staining was performed using a standard biotin–avidin–
peroxidase method with either the mouse monoclonal or goat poly-
clonal antibodies described above. Bound antibody was detected
with biotinylated anti-mouse or anti-goat immuno-globulin and
diaminobenzidine tetrahydrochloride was used to generate signals.
Sections incubated without any primary antibody were employed as
negative controls and failed to exhibit any staining. Liver and kidney
section were also used as negative controls. 
Patients and tissue 
Men with newly diagnosed prostate cancer confirmed histologi-
cally were identified from a pathology department database. All
patients had initially presented with bladder outflow obstruction
and required transurethral resection of the prostate. 37 men (mean
age 74, range 56–82 years) who had not had prior hormone manip-
ulation and had continuous follow up till death or a minimum of 10
years were selected and studied for RAC 3 expression. In this
cohort of patients, 27 went on to have hormonal manipulation (15
bilateral subcapsular orchidectomy, 12 anti-androgen therapy) and
1 patient went on to have a radical prostatectomy. Patients stage
(TNM classification), tumour grade (Gleason sum score), PSA at
diagnosis and survival was recorded. All patients were followed
up in a standard manner with 3–6 monthly clinic appointments.
6 cases of benign prostatic hyperplasia (BPH) were also examined.
Section of liver and kidney were obtained from archival material.
Following formalin fixation and embedding in paraffin, 5 µ m
sections were taken and mounted on glass slides. 
Statistical analysis 
All sections were studied independently by 2 observers without
prior knowledge of the clinical details. 5 sections were previewed
and inter-observer agreement obtained prior to evaluation of the
whole series. Intensity of staining of RAC 3 in prostate cancer
epithelium was graded as weak (+), moderate (++) or strong
(+++). There were no non-staining cases in this series. Where 2 or
more signal intensities were present in one slide, the intensity with
greater than 50% area of staining was taken as the score for that
section. Where there was discrepancy in the scoring, both
observers reviewed the section together and a consensus reached.
Differences in expression of RAC 3 protein in relation to clinical
parameters were examined using the χ 2 and Fishers exact test.
Survival outcome in 36 patients (excluding the 1 who had radical
surgery) was analysed with a Kaplan–Meier plot and the log-rank
test. Survival was defined as the months patients lived following
diagnosis and only deaths directly ascribed to prostate cancer as
recorded in the death registry were counted as terminal events. A
P value of < 0.05 was taken to indicate statistical significance. 
RESULTS 
RAC 3 is expressed in prostate cancer cell lines 
Western analysis was performed on a panel of cancer cell lines to
investigate protein expression. MCF-7 cells are known to express
high levels of the protein while kidney has been demonstrated to
not express RAC 3 at the transcript level. These were used as posi-
tive and negative controls respectively. RAC 3 polyclonal goat
antibody demonstrated strong signals in the MCF-7 cell line while
AR-positive LNCaP cells expressed the highest levels of RAC 3
among the prostate cancer cell lines. AR-negative PC 3 cells also
expressed the protein while in similarly AR-negative DU 145
cells, RAC 3 protein was barely detectable. No signal was
apparent in either normal human kidney lysate or monkey kidney
Cos 7 cells (Figure 1). AR expression was examined on the same
filters by stripping and re-probing with a mouse monoclonal AR
antibody. This demonstrated AR expression in LNCaP cells and
lower levels in MCF-7 cells. Loading was verified by probing with
an  α -tubulin-specific antibody. These results demonstrate that
RAC 3 is expressed in prostate cancer cell lines and remains
expressed in AR-independent cell lines though the levels vary
depending on the cell line. AR-positive prostate cancer cells
however do appear to express the highest amounts of RAC 3. 
RAC 3 interacts with the AR and enhances
transcriptional activity 
To investigate in vivo interaction, immuno-precipitation was
performed utilising cultured LNCaP cells in the presence or
absence of androgens. Androgen receptor was immuno-precipi-
tated from cell lysates, resolved on SDS PAGE and probed with
RAC 3 antibody and the converse experiment performed. In these
studies RAC 3 interacted with the AR (Figure 2A and 2B). This
interaction was strongest in the presence of androgens (mibolerone
10 nM–lane 1) and weakest when the ligand was absent (lane 3).
This suggests that the strength of AR-RAC 3 interaction is ligand-
dependent. No band was detected in lanes with cell lysate only
(lane 4) or with antibody only (lane 5). To confirm the functional
importance of this interaction we performed in vitro transcription
studies. In DU145 cells co-transfected with AR and the PSA
promoter, RAC 3 enhanced PSA promoter activity by up to 3-fold
above levels induced by androgens only and by up to 5-fold above
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Figure 1 RAC 3 is expressed in prostate cancer cell lines. MCF-7 (1) cells
(positive control), LNCaP (2), DU 145 (3), PC 3 (4), Cos 7 (5) cells were run
out concurrently. (A) Western analysis with goat polyclonal anti-human RAC
3, whole human kidney lysate (6) (negative control) did not express RAC 3.
(B) Same filter stripped and re-probed with mouse monoclonal anti-human
AR. (C) Same filter as well as whole human kidney lysate blot stripped and
re-probed with anti-α -tubulin antibody The RAC 3 co-activator in prostate cancer 1931
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basal PSA promoter activity (Figure 3A) in the presence of
mibolerone. Similar studies with the ELE 1α co-activator demon-
strated 5-fold enhancement of reporter activity above levels found
following the transfection of AR and application of mibolerone
and up to 10-fold above basal PSA promoter activity. Unlike RAC
3 however, ELE 1α appeared to have a mild inductive effect on
AR transactivation even in the absence of mibolerone. In duplicate
transfections in Cos 7 cells, similar induction of the AR was
observed and in addition the effect of RAC 3 on AR transcription
was seen to be dose-dependent (Figure 3B). To confirm that the
RAC 3 plasmid was expressed following transfection, Western
blot was performed for the FLAG tag on the pCMX.RAC 3
plasmid. This confirmed high level expression of RAC 3 as
compared to un-transfected cells (Figure 3C). 
RAC 3 is expressed in clinical biopsies at the transcript
level 
Paraffin-embedded sections of benign prostate tissue was subjected
to RNA in situ hybridisation. Anti-sense probes (conferring an
intense blue stain) generated cytoplasmic signals in these (Figure 4A)
while sense probes failed to generate a signal (Figure 4B) showing
only the nuclear counter stain. The anti-sense probe hybridised
strongly to epithelial tissue with little or no signals in the stroma.
This confirmed expression of RAC 3 at the mRNA level in
prostate tissue and suggests that it is expressed predominantly in
epithelium. Sections of prostate cancer similarly probed for RAC 3
also demonstrated similar epithelial signals with little or no
stromal expression (data not shown). 
RAC 3 protein is differentially expressed in BPH and
malignant epithelium 
The mouse monoclonal antibody used for immuno-histochemistry
has not previously been validated for this application. Because of
this, we checked the staining pattern seen with a goat polyclonal
antibody raised against a different region of the protein. This anti-
body was further validated by confirming specificity in detecting
RAC 3 on Western blots with the control cell line MCF-7.
Immuno-histochemistry showed consistent patterns of expression
in BPH and malignant epithelium. In BPH there was generally
weak staining for RAC 3 (Table 1), in addition staining was seen
predominantly in luminal cells rather than basal cells (Figure 4C).
Staining for the AR in adjacent slides of BPH showed that these
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Figure 2 RAC 3 interacts with the AR in vivo in a ligand-dependent manner.
(A) Immuno-precipitation performed on LNCaP cell lysate using goat
polyclonal anti-human RAC 3 and then probed with mouse monoclonal anti-
human AR. (B) Immuno-precipitation performed on LNCaP cell lysate using
mouse monoclonal anti-human AR and then probed with goat polyclonal anti
RAC 3. Lane 1 – cells cultured in DCC with 10 nM mibolerone. Lane 2 – cells
cultured in full media. Lane 3 – cells cultured in DCC only. Lane 4–cell lysate
only with no IP antibody. Lane 5 – IP antibody only with no cell lysate. The
immuno-precipitation band is indicated with an arrow in each case 
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Figure 3 RAC 3 is a co-activator of the AR in prostate cells. Luciferase
results are expressed as fold induction of luciferase activity from basal levels
corrected for transfection efficiency. (A) DU 145 cells were transfected with
50 ng of pcDNA3.AR, 125 ng pPSA.luc, 200 ng pCMV.β gal and 200 ng
pCMX.RAC 3, pSG5.Ele 1α (a known AR co-activator) or empty pSG5 vector
per well of a 24 well plate. Cells were then cultured in the presence or
absence of the synthetic androgen mibolerone. Results shown are the mean
and SD of 3 experiments, each performed in triplicate. (B) Cos 7 cells were
transfected with 50 ng pcDNA3. AR, 125 ng pPSA.luc, 200 ng pCMV.β gal
and 50–200 ng pCMX.RAC 3 per well of a 24 well plate. Results shown are
the mean and SD of 2 experiments, each performed in triplicate. 
(C) Presence of RAC 3 in transfected Cos 7 cells was confirmed by Western
blot against the FLAG tag of the pCMX.RAC 3 vector. Lane 1 RAC 3
transfected Cos 7 cells (100 ng pCMX.RAC 3), Lane 2 untransfected cells 1932 VJ Gnanapragasam et al
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luminal cells were AR-positive while basal cells were AR-nega-
tive (Figure 4D). In cancer there was more homogeneous staining
of epithelial cells and this pattern was apparent regardless of the
grade of the disease with variations only in the intensity of staining
(Figure 4E–H). In both benign and malignant epithelium, RAC 3
appeared to be distributed in the cytoplasmic and nuclear compart-
ments. In many cases we observed that RAC 3 signals were most
evident in the cytoplasm. Stromal signals were equivocally weak
or non-existent in BPH and cancer corresponding to the signal
pattern seen at the mRNA level. Sections of liver and kidney were
also stained as putative-negative controls. As suggested by
previous RNA studies, neither tissue expressed the RAC 3 protein
under standard immuno-histochemical conditions (Figure 4I–J).
Sections of prostate cancer with no primary antibody failed to
exhibit any staining (Figure 4K). 
Expression of RAC 3 is associated with tumour grade,
stage and outcome but not with PSA 
A preliminary series of 37 prostate-cancer patients were studied to
investigate the relationship between RAC 3 staining and disease
progression. Pathological grading of prostate cancer is currently
done using the Gleason sum score. This is the sum of the 2 most
prominent grades of cancer (range 1–5) seen in a specimen of
tissue. In this series Gleason sum score was associated with strong
expression of RAC 3 when the 3 levels of staining intensity were
looked at separately (P = 0.01, n = 37; χ 2) (Table 1). This associa-
tion was further strengthened when the moderate and strong
signals were grouped together (P = 0.0056, Fisher’s exact test).
When tumours were divided into T1/T2 (organ confined) or T3/T4
(non-confined) disease, tumour stage was found to be significantly
associated with signal intensity (P = 0.03, n = 37, χ 2) (Table 1).
Survival outcome analysis in 36 cases (excluding the patient who
had received radical surgery) suggested that moderate or strong
expression was associated with a poorer outcome (Figure 5) when
compared to weak expression (log-rank test P = 0.03). There was,
however, no difference in survival outcome when the moderate-
and strong-expressing groups were compared separately (P = 0.09)
or when the weak and moderate groups were pooled together
(P = 0.19). These preliminary results suggest that the level of
expression of this co-activator in malignant prostate epithelium
has an association with the severity of clinical disease. PSA at
diagnosis was found to bear no relationship to RAC 3 expression. 
DISCUSSION 
In hormone refractory prostate cancer, the role of the AR is uncer-
tain. The cell lines PC 3 and DU 145, for instance, are highly
metastatic and do not express the AR (Culig et al, 1993). In contrast
it is well known that following androgen ablation serum PSA, which
is androgen regulated, begins to rise before clinical evidence of recur-
rent disease is detected. Using immuno-histochemistry, many studies
have shown that the AR continues to be expressed in hormone-
resistant and metastatic cancers (Van der Kwast et al, 1991; Sadi
et al, 1991; Hobisch et al, 1996). In the prostate CWR22 xenograft
model, AR mRNA and protein levels in relapse tumours increase
as hormone independence occurs (Wainstein et al, 1994; Gregory
et al, 1995). Gene amplification of the AR has also been reported
in hormone-relapse prostate cancers (Cher et al, 1996) and
Koivisto et al (1997) showed that AR mRNA levels are also
increased in this group of patients. It is not possible at present
however to manipulate this resurgent AR to control cancer
progression. 
The cytoplasmic AR has been shown to have a signalling
cascade that is independent of nuclear translocation (Peterziel
et al, 1999). It is possible that this pathway becomes increasingly
Table 1 RAC 3 expression is associated with severity of disease. Clinical details of the patients studied with either
BPH or prostate cancer and concomitant RAC 3 expression. Patients with prostate cancer were analysed by stage,
Gleason sum score and PSA level at diagnosis. A P value of < 0.05 was taken as significant. Treatments received
post TURP are also included 
Clinical details  RAC 3 expression  Total  P value 
+ ++  +++ 
BPH 4  2  0  6  — 
Prostate cancer 
Stagea (n = 37) 
T1–T2 7  10  6  23
T3–T4 1  5  8  14  0.03 
Gradeb (n = 37) 
4–6 5  1  2  8
7–10 3  13  13  29  0.01 
PSA (n = 24)  70.9  34.2  89.9
Mean values at diagnosis in ng ml–1 (25.7–154) (2.8–200) (2.7–240)  — NS 
Post TURP treatment (n = 37)
None 3  4  1  8
BSOc 1 5  9  15 
Anti-androgens 2  6  4  14 
Radical surgery  1  0  0  0  — 
aStage of disease is defined as organ confined (T1 and T2) or spread through and beyond the prostate (T3 and T4)
(TNM staging system). bGleason grade is the sum score of the 2 predominant grades of cancer in a section (range
2 to 10) and indicates increasing severity of disease. cBilateral subcapsular orchidectomy. The RAC 3 co-activator in prostate cancer 1933
British Journal of Cancer (2001) 85(12), 1928–1936 © 2001 Cancer Research Campaign
effective when ligand-AR signalling is abrogated. Alternatively,
constituent facilitators of AR nuclear signalling may be over-
expressed. The co-activator CBP for instance has been shown to be
a mediator of transcriptional interference between the AR and the
AP–1/NFκ B transcription factors suggesting that this co-activator
may be an integrator between androgen-mediated and other
signalling pathways (Aarnisalo et al, 1998; Wadgoanker et al,
1999). The role of co-activators in cancer remains elusive. Their
200 ×   200 ×  
200 ×  
200 ×  
400 ×  
400 ×  
400 ×   400 ×  
600 ×   100 ×   100 ×  
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Figure 4 RAC 3 expression in clinical prostate tissue. (A,B) Sections of prostate tissue hybridised with antisense and sense RAC 3 mRNA riboprobes
respectively. (C) Section of BPH stained for RAC 3 protein, prominent luminal cell staining (black arrow) is seen with relative sparing of the basal cells (red
arrow). (D) Section of BPH tissue stained for the androgen receptor showing expression in luminal cells only (black arrow) and negative staining in basal cells
(red arrow). (E,F) High-grade prostate cancer cells with strong staining for RAC 3 protein. (G) Moderately differentiated cancer cells showing moderate staining
for RAC 3 protein. (H) Prostate cancer cells showing weak staining for RAC 3. (I,J) Sections of human liver and kidney respectively with negative immuno-
staining for RAC 3 protein. (K) Section of prostate cancer with no primary antibody showing negative signals 1934 VJ Gnanapragasam et al
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intracellular role and their in vivo interactions are increasing in
complexity. As such, it is not possible to identify a particular co-
activator as being responsible for a particular SHR’s transcrip-
tional activation. Promiscuity, even within the p160 co-activator
family, was emphasized when SRC 1 knockout mice remained
viable with few mature differences from normal mice (Xu et al,
1998). Nevertheless, some interesting studies have linked co-
activators to cancer progression. CBP/p300 has been found to be
mutated in cancer and may be involved in MDM 2 regulation of
p53, a tumour suppressor (Scolnick et al, 1997; Wadgoanker et al,
1999). ARA 70, also designated ELE 1α , was initially identified as
a putative AR-specific co-activator (Yeh and Chang 1996; Alen
et al, 1999) but has been shown to be able to facilitate anti-
androgen signalling to androgen response elements (ARE) thus
postulating a mechanism for the so-called anti-androgen with-
drawal syndrome (Miyamoto et al, 1998). Furthermore, 17-β estra-
diol has been shown to activate AR target genes via its interaction
with the AR-ARA70 complex in the absence of androgens (Yeh
et al, 1998). Levels of SRC 1, the first identified p160 co-activator,
in a study of 21 breast cancers appeared to be able to predict case
response to tamoxifen in patients with recurrent breast cancer
(Berns et al, 1998). Certain members of the family of p160 co-
activators possess histone acetyl transferase (HAT) activity and
histone acetylation is thought to be an important prerequisite for
transcriptional activity of many genes (Hassig and Schreiber 1997).
It is possible that over-expression of HATs may therefore facilitate
the activity of genes important in cancer progression. In acute
myeloid leukaemia for example, the translocation t(8;16)(p11p13),
fusing the MOZ protein to CBP, was found by cytogenetic analysis
of the M4/M5 subtype of the disease. The authors suggest that the
dominant MOZ-CBP fusion protein was mediating leukaemogen-
esis by abnormal levels of acetylation (Borrow et al, 1996). 
RAC 3 possesses HAT activity and shares over 40% homology
with SRC 1, it contains a well-conserved N terminus basic LHL
and period-aryl hydrocarbon receptor-single minded (PAS) A and
B domains (Li et al, 1997). Like SRC 1, RAC 3 contains a number
of LXXLL motifs that interact with liganded receptors. RAC 3
unlike SRC 1 however, appears to be more important in embryonic
development with genetic disruption of RAC 3 resulting in mice
with dwarfism, delayed puberty, reduced female reproductive
function and blunted mammary development (Xu et al, 2000).
RAC 3’s role as an ER co-activator has already been discussed but
in addition to SHRs, RAC 3 has been shown to be a co-activator
for the NFκ B transcription factor (Werbajh et al, 2000). In this
study, RAC 3 was competed for by both NFκ B and the glucocorti-
coid receptor (GR) thus RAC 3 binding to NFκ B was able to abro-
gate NFκ B–GR transrepression. RAC 3 may also be involved in
cell signalling. Font de Mora and Brown (2000) have recently
shown that RAC 3 is phosphorylated by MAPK and MAPK
signalling to the ER is known to stimulate ligand-independent
receptor activity. In this context phosphorylated RAC 3 stimulated
the recruitment of p300 and its associated histone acetyl trans-
ferase activity to the ER complex. The authors postulate that
modulation of ER function by growth factors may therefore be
mediated by MAPK phosphorylation of RAC 3. Other workers
have also shown that RAC 3 interacts with the ubiquitous co-
activator CBP (Li and Chen 1998) which raises the possibility of
RAC 3 being an integrator or recruiter of other co-activators. RAC
3 expression has been identified at the RNA level in human heart,
placenta, muscle, pancreas and prostate but not in lung, liver, brain
or kidney suggesting some tissue specificity (Li and Chen, 1998;
Fujimoto et al, 2001). Protein expression has also been confirmed
in breast and ovarian cancer cell lines (Azorsa and Meltzer, 1999).
The relative specificity of RAC 3 expression in human tissues and
its apparent important role in breast cancer led us to believe that
this co-activator may have a role in the prostate. 
Using RT-PCR (reverse transcriptase-polymerase chain reac-
tion), Fujimoto et al (2001) examined levels of RAC 3 in a panel of
prostate cancer cell lines. They observed low levels of expression
in DU 145 cells, moderate expression in LNCaP cells and high
levels of expression in PC 3 cells. Conversely, a similar study by
Nessler-Menardi et al (2000) again using RT-PCR, found very low
levels of expression in LNCaP cells and moderate expression in
DU 145 cells. These discrepancies may have arisen because RT-
PCR is not inherently a quantitative technique. By Western
analysis we observed most prominent expression of the RAC 3
protein in AR-positive LNCaP cells. Longer exposure of the blot
confirmed weak expression in AR-negative DU 145 cells
compared to moderate expression in AR-negative PC 3 cells and
high expression in LNCaP cells. No signals were apparent in
normal kidney lysate and the monkey kidney cell line Cos 7. We
believe that this analysis of RAC 3 protein levels reflect the true
functional abundance of the co-activator in these cell lines. Both
PC 3 and DU 145 cells do not express AR and the presence and
role of RAC 3, especially in PC3 cells, is intriguing. 
LNCaP cells were predictably strongly positive for the AR
while in MCF-7 cells we observed lower levels of AR expression
and a smaller AR fragment (approximately 80 kDa) which prob-
ably represents a known truncated form of the receptor previously
reported by other researchers (Wilson and Mcfhaul, 1994). In
LNCap cells, immuno-precipitation experiments confirmed that
endogenous AR and RAC 3 interacted physically at the protein
level. This result is in keeping with previous findings by Tan et al
(2000). In their study affinity matrix assays demonstrated that
RAC 3 was able to bind to the AR-ligand-binding domain and
joint AR N terminal and DNA-binding domains but not to the
DNA-binding domain on its own. Our studies have also found that
the strength of the AR-RAC 3 interaction is dependent on the pres-
ence of androgens. 
Transcription studies demonstrated that this interaction was
functional in an in vitro cell model (DU 145 and Cos 7 cells). The
degree of transcriptional enhancement of the wild-type AR was not as
great as that seen with ELE 1α nor that of other reported 
co-activators (Aarnisalo et al, 1998; Brady et al, 1999). Nevertheless,
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Figure 5 RAC 3 expression is associated with disease-specific survival.
RAC 3 staining was stratified as weak (+) or moderate (++) and strong (+++)
for the purpose of survival analysis (n = 36). Patients were followed up for a
mean of 10 years or until death as a direct cause of prostate cancer. A
Kaplan–Meier plot is shown constructed from data on disease specific
survival (log-rank test P = 0.03) The RAC 3 co-activator in prostate cancer 1935
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the degree of enhancement is in agreement with previous reports
of RAC 3 co-activation (Li and Chen, 1998; Tan et al, 2000) and is
similar to that reported for the ER (Anzick et al, 1997).
Experiments in the LNCaP cell line with a native AR also showed
moderate transcriptional enhancement by RAC 3 suggesting that
the effect is not cell type-specific (data not shown). We also
observed that ELE 1α in addition to enhancing liganded AR
activity was able to enhance ligand-independent AR transactiva-
tion which did not occur in the presence of RAC 3. This result
supports the earlier observation that AR-RAC 3 interaction
is ligand-dependent. The AR–ELE 1α complex may also be
responding to other ligands, as has been previously observed
(Miyamoto et al, 1998; Yeh et al, 1998) which do not affect AR-
RAC 3 interaction. While RAC 3 interacts with the AR and is able
to enhance its transcriptional activity, the fact that it is expressed in
AR-independent prostate cells and is over-expressed in non-SHR-
dependent tissue suggests a supplementary role for RAC 3 in cancer
progression that appears to be independent of the AR. Another mode
of RAC 3 activity in prostate cancer cells may be via its well charac-
terised interaction with the ER (Anzick et al, 1997; Tikkanen et al,
2000; Xu et al, 2000). The oestrogen receptor (ER) has been shown
to be present in human prostate cancer and pre-malignant lesions
(Bonkhoff et al, 1999), while the prostate cell lines LNCaP, DU 145
and PC 3 have been shown to express the β isoform of the receptor
(Lau et al, 2000). From these studies, ER status appears to be an
important factor in prostate cancer progression. It is possible that in
addition to its co-activation of the AR, RAC3 may be involved in
enhancing ER activity in prostate cancer cells.
In situ hybridisation confirmed strong expression of RAC 3
mRNA in epithelial cells with only few scattered signals in the
stroma. This was confirmed by the immuno-histochemistry data
which detected only a few scattered signals in the stroma. In clin-
ical prostate tissue we found that protein expression of RAC 3
differed between benign and malignant prostate epithelium. In
benign tissue more prominent staining was seen in luminal cells as
compared to basal cells while in cancer, the staining was more
homogeneous. This may be due to the fact that undifferentiated
basal cells do not express the androgen receptor while luminal
cells do. This selectivity is lost in malignant epithelium which is
known to be of a luminal phenotype. Interestingly we found that
RAC 3 was expressed in both the cytoplasm and nucleus of cells.
While this may represent an artifact of the fixative procedure, it
could also be due to RAC 3 interacting with the AR in both
compartments. Co-localisation studies (AR and RAC 3) would
help to clarify this. Interestingly, studies involving other AR co-
activators in the prostate e.g. FHL 2 have also demonstrated both
cytoplasmic and nuclear staining (Muller et al, 2000). 
To correlate staining with the severity of disease we used a
system of graded intensities. All our patients had 10 years or more
follow up and Gleason sum scoring was performed by an experi-
enced pathologist. Grade and stage of disease but not PSA at diag-
nosis, was found to correlate significantly with the intensity of
RAC 3 staining. To investigate if expression RAC 3 had an associ-
ation with clinical outcome, we proceeded to analyse signal inten-
sities with respect to disease-specific survival. In this retrospective
cohort, tumours expressing moderate or strong levels of RAC 3
appeared to have a poorer outcome. This association was lost
however if the 3 signal intensities were examined separately.
These initial results need to be verified with a larger study but is
nevertheless suggestive of a role for over-expression of RAC 3 in
prostate cancer progression. 
In conclusion, we have shown evidence for an important role for
RAC 3 in the prostate. We have demonstrated that this co-activator
interacts with endogenous AR in a ligand-dependent manner and
functionally enhances transcriptional activity in prostate cancer
cells. We demonstrate expression of the protein in both androgen-
dependent and -independent prostate cell lines and show that RAC
3 is expressed at the mRNA and protein level in prostate biopsies.
Furthermore we found preliminary evidence that the expression
differed between benign and malignant epithelium, and that
moderate and strong staining for RAC 3 was associated with 
high-grade, late-stage disease and a poor outcome. Taken together
these data suggest that RAC 3 is an important co-activator in
prostate cancer and warrants further study to define its role
in prostate cancer progression. 
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